NVDA vs PN

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.

PN exhibits a paradoxical profile: while the Piotroski F-Score of 5/9 suggests stable financial health and valuation multiples (P/B 0.21, P/S 0.13) are mathematically deep-value, the price action is catastrophic. The stock has collapsed over 93% in the last year, falling from a high of $87.40 to $3.13, indicating a severe loss of market confidence or potential fundamental impairment not yet reflected in the lagging accounting data. Despite strong YoY revenue growth of 42.9%, the company remains unprofitable with negative margins and a total lack of technical support.